Table 2.
Group 1 | Group2 | p-value |
---|---|---|
Peptide length | ||
Non-spliced products | Non-spliced synthesis artifacts | <2e-16 |
Non-spliced products | Non-spliced random control | <2e-16 |
Non-spliced synthesis artifacts | Non-spliced random control | <2e-16 |
cis spliced products | cis spliced synthesis artifacts | <2e-16 |
cis spliced products | cis spliced random control | <2e-16 |
cis spliced synthesis artifacts | cis spliced random control | <2e-16 |
trans spliced products | trans spliced synthesis artifacts | <2e-16 |
trans spliced products | trans spliced random control | <2e-16 |
trans spliced synthesis artifacts | trans spliced random control | <2e-16 |
Non-spliced products | cis spliced products | <2e-16 |
cis spliced products | trans spliced products | <2e-16 |
Non-spliced products | trans spliced products | <2e-16 |
Splice-reactant length: SR1 | ||
Normal cis spliced products | Normal cis spliced synthesis artifacts | <2e-16 |
Normal cis spliced products | Normal cis spliced random control | <2e-16 |
Normal cis spliced synthesis artifacts | Normal cis spliced random control | <2e-16 |
Reverse cis spliced products | Reverse cis spliced synthesis artifacts | <2e-16 |
Reverse cis spliced products | Reverse cis spliced random control | 6.3e-16 |
Reverse cis spliced synthesis artifacts | Reverse cis spliced random control | 7.9e-13 |
trans spliced products | trans spliced synthesis artifacts | <2e-16 |
trans spliced products | trans spliced random control | <2e-16 |
trans spliced synthesis artifacts | trans spliced random control | 1.8e-11 |
Splice-reactant length: SR2 | ||
Normal cis spliced products | Normal cis spliced synthesis artifacts | <2e-16 |
Normal cis spliced products | Normal cis spliced random control | 0.055 |
Normal cis spliced synthesis artifacts | Normal cis spliced random control | <2e-16 |
Reverse cis spliced products | Reverse cis spliced synthesis artifacts | <2e-16 |
Reverse cis spliced products | Reverse cis spliced random control | <2e-16 |
Reverse cis spliced synthesis artifacts | Reverse cis spliced random control | <2e-16 |
trans spliced products | trans spliced synthesis artifacts | <2e-16 |
trans spliced products | trans spliced random control | <2e-16 |
trans spliced synthesis artifacts | trans spliced random control | <2e-16 |
Intervening sequence length | ||
Normal cis spliced products | Normal cis spliced synthesis artifacts | 0.013 |
Normal cis spliced products | Normal cis spliced random control | <2e-16 |
Normal cis spliced synthesis artifacts | Normal cis spliced random control | <2e-16 |
Reverse cis spliced products | Reverse cis spliced synthesis artifacts | 0.042 |
Reverse cis spliced products | Reverse cis spliced random control | 0.014 |
Reverse cis spliced synthesis artifacts | Reverse cis spliced random control | 0.14 |
Group 1 is compared to group 2 using Kolmogorov-Smirnov test. Resulting p-values are listed.